These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 18513971

  • 1. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis.
    Ralph AP, Kelly PM, Anstey NM.
    Trends Microbiol; 2008 Jul; 16(7):336-44. PubMed ID: 18513971
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunotherapy for TB.
    Doherty TM.
    Immunotherapy; 2012 Jun; 4(6):629-47. PubMed ID: 22788130
    [Abstract] [Full Text] [Related]

  • 4. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
    Martins M, Viveiros M, Ramos J, Couto I, Molnar J, Boeree M, Amaral L.
    Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
    [Abstract] [Full Text] [Related]

  • 5. Human macrophage host defense against Mycobacterium tuberculosis.
    Liu PT, Modlin RL.
    Curr Opin Immunol; 2008 Aug; 20(4):371-6. PubMed ID: 18602003
    [Abstract] [Full Text] [Related]

  • 6. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.
    Martins M, Viveiros M, Couto I, Amaral L.
    Int J Tuberc Lung Dis; 2009 May; 13(5):569-73. PubMed ID: 19383188
    [Abstract] [Full Text] [Related]

  • 7. Macrophages and Mycobacterium tuberculosis: the key to pathogenesis.
    Rook GA.
    Immunol Ser; 1994 May; 60():249-61. PubMed ID: 8251572
    [No Abstract] [Full Text] [Related]

  • 8. Reconsidering adjuvant immunotherapy for tuberculosis.
    Wallis RS.
    Clin Infect Dis; 2005 Jul 15; 41(2):201-8. PubMed ID: 15983916
    [Abstract] [Full Text] [Related]

  • 9. Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis.
    Martineau AR.
    Proc Nutr Soc; 2012 Feb 15; 71(1):84-9. PubMed ID: 22123447
    [Abstract] [Full Text] [Related]

  • 10. Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis.
    Schön T, Lerm M, Stendahl O.
    J Intern Med; 2013 Apr 15; 273(4):368-82. PubMed ID: 23331325
    [Abstract] [Full Text] [Related]

  • 11. Synergistic action of vitamin D and retinoic acid restricts invasion of macrophages by pathogenic mycobacteria.
    Anand PK, Kaul D, Sharma M.
    J Microbiol Immunol Infect; 2008 Feb 15; 41(1):17-25. PubMed ID: 18327422
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers.
    Rivas-Santiago CE, Hernández-Pando R, Rivas-Santiago B.
    Immunotherapy; 2013 Oct 15; 5(10):1117-26. PubMed ID: 24088080
    [Abstract] [Full Text] [Related]

  • 13. Novel N-aryl- and N-heteryl phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis.
    De Logu A, Palchykovska LH, Kostina VH, Sanna A, Meleddu R, Chisu L, Alexeeva IV, Shved AD.
    Int J Antimicrob Agents; 2009 Mar 15; 33(3):223-9. PubMed ID: 19070992
    [Abstract] [Full Text] [Related]

  • 14. [Immunotherapy in the combined treatment of chronic destructive pulmonary tuberculosis].
    Ivanova LA.
    Probl Tuberk; 1994 Mar 15; (3):16-9. PubMed ID: 7937662
    [Abstract] [Full Text] [Related]

  • 15. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES, Mallampalli A.
    Ther Adv Respir Dis; 2008 Dec 15; 2(6):401-8. PubMed ID: 19124385
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar 15; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 17. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
    Lai CC, Tan CK, Huang YT, Chou CH, Hung CC, Yang PC, Luh KT, Hsueh PR.
    Clin Infect Dis; 2008 Oct 01; 47(7):e57-63. PubMed ID: 18715157
    [Abstract] [Full Text] [Related]

  • 18. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J, Doherty TM.
    APMIS; 2009 May 01; 117(5-6):440-57. PubMed ID: 19400867
    [Abstract] [Full Text] [Related]

  • 19. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital.
    Meskel DW, Abate G, Lakew M, Goshu S, Aseffa A.
    Ethiop Med J; 2008 Jul 01; 46(3):219-25. PubMed ID: 19271385
    [Abstract] [Full Text] [Related]

  • 20. [Some regularities of an immune response in patients with pulmonary tuberculosis and drug-resistant Mycobacterium strains].
    Sakharova IIa, Ariél' BM, Knoring BE, Skvortsova LA, Vasil'eva GIu, Vishnevskiĭ BI, Pogodaeva SS.
    Probl Tuberk Bolezn Legk; 2008 Jul 01; (12):22-7. PubMed ID: 19230184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.